Meanwhile, these cardiovascular outcomes trials have also demonstrated that SGLT2 inhibitors may be renoprotective, slowing the progression of renal disease in patients with or without T2DM (7, 25–27). The gene discussed is SLC5A2; the disease is kidney disorder.